<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0912211449
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PLEGRIDY 63-94 mcg solution for injection
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PEGINTERFERON BETA-1A
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        63
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3455.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="VETTER PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            VETTER PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Biogen Idec B.V-Natherland
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L03AB13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p><strong>What Plegridy is</strong></p><p>The active substance in Plegridy is peginterferon beta‑1a. Peginterferon beta‑1a is a modified long‑acting form of interferon. Interferons are natural substances made in the body to help protect from infections and diseases.</p><p>&nbsp;</p><p>What Plegridy is used for</p><p><strong>This medicine is used to treat relapsing-remitting multiple sclerosis (MS) in adults aged 18 or over</strong><strong>.</strong></p><p>MS is a long term illness that affects the central nervous system (CNS), including the brain and spinal cord, in which the body&rsquo;s immune system (its natural defences) damages the protective layer (myelin) that surrounds the nerves in the brain and spinal cord. This disrupts the messages between the brain and other parts of the body, causing the symptoms of MS. Patients with relapsing-remitting MS have periods when the disease is not active (remission) in between flare-ups of symptoms (relapses).</p><p>&nbsp;</p><p><strong>Everyone has their own set of MS symptoms.</strong> These can include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling off-balance or light headed, walking problems, stiffness and muscle spasms, tiredness, numbness in the face, arms or legs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute or chronic pain, bladder and bowel problems, sexual problems and problems with vision</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty thinking and concentrating, depression.</p><p>&nbsp;</p><p>How Plegridy works</p><p><strong>Plegridy seems to work by stopping the body&rsquo;s immune system from damaging your brain and spinal cord. </strong>This can help to reduce the number of relapses that you have and slow down the disabling effects of MS. Treatment with Plegridy can help to prevent you from getting worse, although it will not cure MS.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p><strong>Do not use Plegridy</strong><strong> </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are allergic </strong>to peginterferon beta‑1a, interferon beta-1a or any of the ingredients of this medicine (listed in section 6). See section 4 for the symptoms of an allergic reaction.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have severe depression</strong> or think about committing suicide.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p><strong>Talk to your doctor if you have ever had:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Depression </strong>or problems affecting your mood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Thoughts about committing suicide</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may still prescribe Plegridy for you, but it&rsquo;s important to let your doctor know if you have had depression or any similar problems affecting your mood in the past.</p><p><strong>&nbsp;</strong></p><p><strong>Talk to your doctor, pharmacist or nurse</strong> before injecting Plegridy <strong>if you have any of the conditions listed below. </strong>They may get worse while using Plegridy<strong>: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Serious liver or kidney problems</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Irritation at an injection site, </strong>which can lead to skin and tissue damage (<em>injection site necrosis</em>). When you are ready to inject, carefully follow the instructions in section 7 &ldquo;<em>Instructions for injecting Plegridy pre-filled pen</em>&rdquo;, at the end of this leaflet. This is to reduce the risk of injection site reactions.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Epilepsy </strong>or other seizure disorders, not controlled by medicine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Heart problems</strong>, which can cause symptoms such as chest pain (<em>angina</em>), particularly after any activity; swollen ankles, shortness of breath (<em>congestive heart failure</em>); or an irregular heartbeat (<em>arrhythmia</em>).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Thyroid problems</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>A low number of white blood cells or platelets</strong>, which can cause an increased risk of infection, or bleeding</p><p><strong>&nbsp;</strong></p><p><strong>Other things to consider when using Plegridy</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will need blood tests to determine your numbers of blood cells, blood chemistry and your levels of liver enzymes. These will be performed before you start using Plegridy, regularly after treatment with Plegridy has been initiated and then periodically during treatment, even if you have no particular symptoms. These blood tests will be in addition to the tests which are normally done to monitor your MS.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The functioning of your thyroid gland will be checked regularly or whenever thought necessary by your doctor for other reasons.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood clots in the small blood vessels may occur during your treatment. These blood clots could affect your kidneys. This might happen several weeks to several years after starting Plegridy. Your doctor may want to check your blood pressure, blood (platelet count) and the function of your kidneys.</p><p>&nbsp;</p><p>If you accidentally prick yourself or someone else with the needle in Plegridy, the area affected should be washed <strong>immediately</strong> with soap and water and a <strong>doctor or nurse should be contacted </strong><strong>as soon as possible.</strong></p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Plegridy is <strong>not to be used</strong> in children and adolescents below 18&nbsp;years old. The safety and effectiveness of Plegridy in this age group are not known.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Plegridy</strong></p><p>Plegridy should be used carefully with medicines that are broken down in the body by a group of proteins called &ldquo;cytochrome P450&rdquo; (e.g. some medicines used for epilepsy or depression).</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, especially those used to treat epilepsy or depression. This includes any medicines obtained without a prescription.</p><p>&nbsp;</p><p>Sometimes you will need to remind other healthcare professionals that you are being treated with Plegridy. For example, if you are prescribed other medicines, or if you have a blood test. Plegridy may affect the other medicines or the test result.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>No harmful effects on the breastfed newborn/infant are anticipated. Plegridy can be used during breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Plegridy has no or negligible influence on the ability to drive and use machines.</p><p><strong>&nbsp;</strong></p><p><strong>Plegridy contains sodium </strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg), that is to say it is essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>The usual dose</strong></p><p>One injection of Plegridy 125&nbsp;micrograms every 14&nbsp;days (every two weeks). Try to use Plegridy at the same time on the same day, every time you inject.</p><p><strong>&nbsp;</strong></p><p><strong>Starting Plegridy</strong></p><p>If you are new to Plegridy, your doctor may advise you to gradually increase your dose so that you can adjust to the effects of Plegridy<strong> </strong>before taking the full dose. You will be provided with an Initiation Pack containing your first 2&nbsp;injections: one orange pen with Plegridy 63&nbsp;micrograms (for day 0) and one blue pen with Plegridy 94&nbsp;micrograms (for day 14).</p><p>&nbsp;</p><p>After that you will be provided with a maintenance pack containing grey pens with Plegridy 125&nbsp;micrograms (for day 28 and then every two weeks).</p><p>&nbsp;</p><p>Read the instructions in section 7 &ldquo;<em>Instructions for injecting Plegridy pre-filled pen</em>&rdquo; at the end of this leaflet before you start using Plegridy.</p><p>Use the record table printed on the inside of the lid of the Initiation Pack to keep a track of your injection dates.</p><p>&nbsp;</p><p><strong>Injecting yourself</strong></p><p>Plegridy is to be injected under the skin (<em>subcutaneous injection</em>). Alternate the sites you use for injections. Do not use the same injection site for consecutive injections.</p><p>You can inject Plegridy yourself without the help of your doctor, if you have been trained how to do this.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Read and follow the advice given in the instructions in section 7 &ldquo;<em>Instructions for injecting Plegridy pre-filled pen</em>&rdquo; before you start.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have trouble</strong> handling the pen, ask your doctor or nurse who may be able to help.</p><p>&nbsp;</p><p>How long to use Plegridy</p><p>Your doctor will tell you how long you need to keep using Plegridy. It is important to continue using Plegridy regularly. Do not make changes unless your doctor tells you.</p><p>&nbsp;</p><p>If you use more Plegridy than you should</p><p>You must only inject Plegridy once every 2&nbsp;weeks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have used more than one injection of Plegridy in a 7‑day period, contact your doctor or nurse straight away.</p><p>&nbsp;</p><p>If you forget to use Plegridy</p><p>You need to inject Plegridy once every 2&nbsp;weeks. This regular schedule helps to deliver the treatment as evenly as possible.</p><p>&nbsp;</p><p>If you do miss your usual day, inject as soon as you can and carry on as usual. However, do not inject more than once in a 7‑day period. Do not use two injections to make up for a missed injection.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Liver problems</strong></p><p><em>(common - may affect up to 1 in 10&nbsp;people)</em></p><p>If you get any of these symptoms:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellowing of your skin or the whites of your eyes</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching all over</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick, being sick <em>(nausea and vomiting)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Easy bruising of the skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact a doctor immediately. They may be signs of a possible liver problem.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Depression</strong></p><p><em>(common - may affect up to 1 in 10&nbsp;people)</em></p><p>If you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feel unusually sad, anxious or worthless or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have thoughts about suicide</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact a doctor immediately.</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Serious allergic reaction</strong></p><p><em>(uncommon - may affect up to 1 in 100&nbsp;people)</em></p><p>If you get any of these:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling around the face (lips, tongue or throat)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rashes or redness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact a doctor immediately.</p><p><strong>&nbsp;</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Seizures</strong></p><p><em>(uncommon - may affect up to 1 in 100&nbsp;people)</em></p><p>If you have a seizure or a fit<em> </em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact a doctor immediately.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Injection site damage</strong></p><p><em>(rare - may affect up to 1 in 1,000&nbsp;people)</em></p><p>If you get any of these symptoms:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any break in the skin together with swelling, inflammation or fluid leaking around the injection site</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact a doctor for advice.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Kidney problems including scarring that may reduce your kidney function </strong></p><p><em>(rare - may affect up to 1 in 1,000&nbsp;people)</em></p><p>If you get some or all of these symptoms:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Foamy urine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling, particularly in the ankles and eyelids, and weight gain.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact a doctor as they may be signs of a possible kidney problem.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood problems </strong></p><p><em>(rare - may affect up to 1 in 1,000&nbsp;people)</em></p><p>The following may occur: Blood clots in the small blood vessels that can affect your kidneys (thrombotic thrombocytopenic purpura or haemolytic uremic syndrome). Symptoms may include increased bruising, bleeding, fever, extreme weakness, headache, dizziness or light-headedness.&nbsp; Your doctor may find changes in your blood and the function of your kidneys.</p><p>&nbsp;</p><p>If you get some or all of these symptoms:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased bruising or bleeding</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Extreme weakness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache, dizziness or light-headedness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact a doctor immediately.</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p><strong>Very common side effects </strong></p><p><em>(may affect more than 1 in 10&nbsp;people)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flu-like symptoms.&nbsp; These symptoms are not really flu, see below. You can&rsquo;t pass it on to anyone else.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain (<em>myalgia</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in your joints, arms, legs or neck (<em>arthralgia</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling weak and tired (<em>asthenia</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness, itching or pain around the place you have injected</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of these effects trouble you, contact a doctor.</p><p>&nbsp;</p><p><strong>Flu-like symptoms</strong></p><p>Flu-like symptoms are more common when you first start using Plegridy. They gradually get less as you keep using your injections. See below for simple ways to manage these flu-like symptoms if you get them.</p><p>&nbsp;</p><p>Three simple ways to help reduce the impact of flu-like symptoms:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Consider the timing of your Plegridy injection. The start and end of flu-like symptoms are different for every patient. On average, flu-like symptoms begin approximately 10&nbsp;hours after injection and last between 12 and 24&nbsp;hours.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take paracetamol or ibuprofen half an hour before your Plegridy injection and continue to take paracetamol or ibuprofen for the duration of your flu-like symptoms. Speak to your doctor or pharmacist about how much to take and how long to take it.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a fever, drink plenty of water to keep you hydrated.</p><p>&nbsp;</p><p><strong>Common side effects</strong></p><p><em>(may affect up to 1 in 10&nbsp;people)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling or being sick <em>(nausea or vomiting)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss (<em>alopecia</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchy skin (<em>pruritus</em>)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in body temperature</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes around the place you have injected such as swelling, inflammation, bruising, warmth, rash or colour change</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in your blood which might cause tiredness or reduced ability to fight infection</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increases in liver enzymes in the blood (will show up in blood tests)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of these effects trouble you, talk to your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon side effects</strong></p><p><em>(may affect up to 1 in 100&nbsp;people)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hives</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in your blood which might cause unexplained bruising or bleeding.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of these effects trouble you, talk to your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;Frequency not known</strong></p><p><em>(frequency cannot be estimated from the available data)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary arterial hypertension: A disease of severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels that carry blood from the heart to the lungs. Pulmonary arterial hypertension has been seen at various time points during treatment, including several years after starting treatment with interferon beta-products.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in section 6. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>In order to improve the traceability of this medicine, your doctor or pharmacist should record the name and the lot number of the product you have been given in your patient file. You may also wish to make a note of these details in case you are asked for this information in the future.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and the label after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from light. Only open the pack when you need a new pen.</p><p>&nbsp;</p><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator</strong> (fridge), 2&ordm;-8&ordm;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze. Throw away any Plegridy that is accidentally frozen.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Plegridy can be kept outside a fridge at room temperature (up to 30&deg;C) for up to 7&nbsp;days but it must be kept <strong>away from light</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Packs can be taken out of the fridge and then put back in a fridge more than once if you need to.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Make sure the time the pens spend out of a fridge is <strong>no more than 7&nbsp;days in total</strong>.&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Throw away any pen that is kept out of the fridge for more than 7&nbsp;days.&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are unsure of the number of days you have kept a pen out of the fridge, throw the pen away.&nbsp;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice any of the following:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the pen is broken.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the solution is coloured, cloudy or you can see particles floating in it.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>The active ingredient is peginterferon beta‑1a.</p><p>&nbsp;</p><p>Each 63&nbsp;microgram pre‑filled pen contains 63&nbsp;micrograms of peginterferon beta‑1a in 0.5&nbsp;mL solution for injection.</p><p>Each 94&nbsp;microgram pre‑filled pen contains 94<strong>&nbsp;</strong>micrograms of peginterferon beta‑1a in 0.5&nbsp;mL solution for injection.</p><p>Each 125&nbsp;microgram pre‑filled pen contains 125&nbsp;micrograms of peginterferon beta‑1a in 0.5&nbsp;mL solution for injection.</p><p>&nbsp;</p><p>The other ingredients<strong> </strong>are: Sodium acetate trihydrate, acetic acid glacial, arginine hydrochloride, polysorbate&nbsp;20 and water for injections (see section 2 &ldquo;Plegridy contains Sodium&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 Plegridy is a clear and colourless solution for injection in a glass pre filled pen with an attached needle.

Pack sizes:
- The Plegridy Initiation Pack contains one orange pre filled pen of 63 micrograms and one blue pre filled pen of 94 micrograms. 
- The 125 micrograms grey pens are provided in a pack containing two pre filled pens.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p><strong>Marketing Authorisation Holder and Final batch releaser</strong></p><p>Biogen Netherlands B.V.</p><p>Prins Mauritslaan 13</p><p>1171 LP Badhoevedorp</p><p>The Netherlands</p><p>Telephone: +31 (0) 20 5422 000</p><p>E-mail: medinfo.netherlands@biogen.com</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Dosage form manufacturer</strong></p><p>Vetter Pharma-Fertigung GmbH &amp; Co. KG</p><p>Sch&uuml;tzenstrasse 87 and 99 &ndash; 101</p><p>88212 Ravensburg</p><p>Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 06/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما هو </strong><strong>بليغريدي</strong></p><p dir="RTL">المادة الفعالة في بليغريدي هي بيغ إنترفيرون بيتا ١أ. وهذه المادة هي شكل مُعدَّل، طويل المفعول من الإنترفيرون. الإنترفيرونات هي مواد طبيعية ينتجها الجسم لتساعد في حمايته من الالتهابات والأمراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دواعي استعمال</strong><strong> </strong><strong>بليغريدي</strong></p><p dir="RTL"><strong>يستعمل الدواء لعلاج التصلُّب المتعدد الناكس المتراجع لدى البالغين من عمر 18 عامًا أو أكثر.</strong> التصلُّب المتعدد هو مرض طويل الأمد يُؤثر على الجهاز العصبي المركزي، بما في ذلك المخ والحبل النخاعي، والذي يدمر فيه النظام المناعي للجسم (دفاعاته الطبيعية) الطبقة الواقية (الميالين) التي تحيط بالأعصاب في الدماغ والحبل النخاعي. يعمل هذا على تعطيل الرسائل المتبادلة بين المخ وأجزاء الجسم الأخرى، مما يسبب أعراض التصلُّب المتعدد. يشهد المرضى الذين يُعانون من التصلُّب المتعدد الناكس المتراجع فترات؛ حيث يكون المرض غير نشط (التراجع) فيما بين نوبات تفاقم الأعراض (الانتكاسات).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كل شخص تظهر لديه مجموعة خاصة من أعراض التصلُّب المتعدد.</strong> وهذه الأعراض يمكن أن تشمل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم الاتزان أو الدوخة/ مشاكل في المشي، التصلُّب، وتشنجات في العضلات، وتعب، وخدر في الوجه والذراعين والساقين. &nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام حادة أو مزمنة، مشاكل في المثانة والأمعاء، ومشاكل جنسية، ومشاكل في الرؤية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التفكير والتركيز، واكتئاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يعمل بليغريدي</strong></p><p dir="RTL"><strong>يبدو أن بليغريدي يعمل بإيقاف الجهاز المناعي للجسم عن تدمير دماغك</strong><strong> </strong><strong>&nbsp;</strong><strong>والحبل النخاعي لديك.</strong> يمكن لهذا أن يساعد على خفض عدد الانتكاسات التي تتعرض لها، وأن يبطئ من الآثار المُعوقة للتصلُّب المتعدد. يُمكن أن يساعد العلاج باستعمال بليغريدي في الوقاية من تفاقم حالتك المرضيّة من أن تزداد سوءًا، على الرغم من أنه لن يشفي من التصلُّب المتعدد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لا تستعمل بليغريدي، في الحالات التالية:</strong></p><p>&middot;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه بيغ إنترفيرون بيتا ١أ، أو الإنترفيرون بيتا ١أ، أو أيٍّ من المكونات الأخرى في هذا الدواء (المدرجة في القسم ٦). انظر القسم ٤ للتعرُّف على أعراض رد الفعل التحسسي.</p><p>&middot;&nbsp;&nbsp; إذا كان لديك اكتئابٌ حادٌّ أو تُفكِّر في الانتحار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong><strong> </strong></p><p><strong>تعرضت سابقًا إلى:</strong><strong> </strong><strong>تحدَّث مع طبيبك إذا كنت قد</strong><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الاكتئاب</strong> أو مشاكل تؤثر على حالتك المزاجية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تراودك</strong><strong> </strong><strong>أفكار حول الانتحار</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من الممكن أن يستمر طبيبك في وصف بليغريدي لك، ولكن من المهم أن تخبره ما إذا كان الاكتئاب أو أيُّ مشاكل مماثلة تؤثر على حالتك المزاجية في الماضي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحدث إلى طبيبك المعالج أو الصيدلي</strong> أو الممرضة قبل حقن بليغريدي <strong>إذا كنت تشهد حدوث أيٍّ من هذه الأعراض المذكورة أدناه</strong>. ربما تتفاقم لديك الأعراض خلال استعمالك لدواء بليغريدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل خطرة في الكبد أو الكلى.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تهيُّج</strong><strong> في أحد مواضع الحقن،</strong> والذي أدى إلى تلف في الجلد والأنسجة لديك (موت الأنسجة في موضع الحقن). عندما تكون مستعدًا للحقن، اتبع التعليمات الواردة في القسم رقم ٧ &nbsp;&quot; تعليمات عن كيفية الحقن بواسطة قلم الحقن بليغريدي المعبَّأ مُسبقًا&quot;، في نهاية هذه النشرة. هذا من أجل تقليل مخاطر تفاعلات موضع الحقن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الصرع</strong><strong> </strong>أو اضطرابات أخرى تنطوي على حدوث نوبات، لا يمكن السيطرة عليها باستعمال الأدوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل في القلب،</strong> والتي يمكن أن تسبب حدوث أعراض مثل آلام الصدر (الذبحة الصدرية)، وخصوصًا بعد أي نشاط، تورم الكاحلين، أو ضيق التنفس (فشل القلب الاحتقاني)؛ أو عدم انتظام نبضات القلب (اضطراب النظم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل الغدة الدرقية.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>انخفاض</strong><strong> عدد خلايا الدم البيضاء أو الصفيحات،</strong> والتي يُمكن أن تسبب زيادة خطر حدوث عدوى، أو النزيف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>احتياطات أخرى يجب مراعاتها عند استخدام بليغريدي</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستحتاج للخضوع إلى اختبارات دم لتحديد أعداد خلايا الدم لديك، وكيمياء الدم، ومستويات إنزيمات الكبد لديك. ينبغي القيام بهذا قبل أن تبدأ في استعمال دواء بليغريدي، وعادةً بعد البدء بالعلاج باستعمال بليغريدي، ثم بشكلٍ دوريٍّ خلال العلاج، حتى إذا لم يكن لديك أعراض معينة. اختبارات الدم هذه تكون بالإضافة إلى الاختبارات التي عادةً ما يتم إجراؤها لرصد حالة التصلُّب المتعدد لديك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأداء الوظيفي للغدة الدرقية لديك سيتم فحصه بشكلٍ دوريٍّ، أو وقتما يكون هناك اعتقاد بضرورة ذلك من قِبل طبيبك لأسباب أخرى.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث جلطات دموية في الأوعية الدموية الصغيرة أثناء العلاج. يمكن أن تؤثر هذه الجلطات الدموية على الكليتين. قد يحدث هذا عدة أسابيع إلى عدة سنوات بعد بدء بليغريدي. قد يرغب طبيبك في فحص ضغط الدم والدم (عدد الصفائح الدموية) ووظيفة الكليتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وإذا وخزت نفسك أو شخصًا آخر عن طريق الخطأ بإبرة تحتوي على داوء بليغريدي؛ فإن المنطقة التي تم حقنها ينبغي غسلها <strong>على الفور</strong> بالماء والصابون، وينبغي الاتصال بإحدى <strong>الممرضات أو أحد الأطباء في أقرب وقتٍ ممكن.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><strong>يتعين عدم استعمال</strong> دواء بليغريدي لدى الأطفال والمراهقين ما دون ال ١٨ من العمر، حيث إن سلامة وفعالية بليغريدي في هذه الفئة العمرية غير معروفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وبليغريدي</strong></p><p dir="RTL">ينبغي استعمال بليغريدي بحرص مع الأدوية التي تتحلل في الجسم عن طريق مجموعة من البروتينات تسمى &quot;السيتكرم ب-٤٥٠&quot;، على سبيل المثال: (بعض الأدوية المستخدمة في علاج الصرع أو الاكتئاب).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك المعالج أو الصيدلي إذا كانت تتناول، أو تناولت مؤخرًا، أو ربما تتناول أيَّ دواء آخر، وخصوصا تلك الأدوية التي تستخدم لعلاج الصرع أو الاكتئاب. يشمل هذا أيَّ أدوية يتم الحصول عليها من دون وصفة طبيَّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في بعض الأحيان سوف تحتاج &nbsp;إلى تذكير مهني الرعاية الصحية الآخرين بأنك تُعالَج باستعمال بليغريدي. على سبيل المثال: إذا وصفت لك أدوية أخرى، أو إذا خضعت لاختبار دم، فربما يؤثر بليغريدي على الأدوية الأخرى أو نتائج الاختبار.&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملًا، أو تظنين أنك &nbsp;حامل، أو تخططين لإنجاب طفل، فاسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء. من غير المتوقع أن يكون للدواء تأثير ضار على المولود / الرضيع الذي يرضع من الثدي. يمكن استعمال بليغريدي أثناء الرضاعة الطبيعية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong></p><p>بليغريدي ليس له أيُّ تأثير يُذكر على القدرة على القيادة واستعمال الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بليغريدي يحتوي على الصوديوم</strong></p><p dir="RTL">كلُّ حقنة تحتوي على أقل من ١ مليمول من الصوديوم (٢٣ ملغ). أي أن هذا الدواء في الأساس &quot;خالٍ من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">استعمل بليغريدي دائمًا تمامًا مثلما أخبرك طبيبك المعالج أو الصيدلي. تحقق من الأمر مع طبيبك المعالج أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة المعتادة:</strong></p><p dir="RTL">حقنة بليغريدي ١٢٥ ميكروغرام كل ١٤ يومًا (كل أسبوعين). حاول أن تستخدم بليغريدي في نفس الوقت من نفس اليوم، في كل مرة تقوم بعمليات الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البدء باستعمال بليغريدي</strong></p><p dir="RTL">إذا كنت تستعمل بليغريدي لأول مرة؛ فقد ينصحك طبيبك بزيادة جرعتك تدريجيًّا؛ بحيث يُمكنك التكيُّف مع الأعراض التي يسببها بليغريدي قبل تناول الجرعة الكاملة. سيتم تزويدك بعبوة البدء؛ والتي تحتوي على أول حقنتين: حقنة واحدة ذات لون برتقالي تحتوي على بليغريدي ٦٣ ميكروغرام (اليوم ٠)، وحقنة واحدة زرقاء تحتوي على بليغريدي ٩٤ ميكروغرام (اليوم الرابع عشر).</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد ذلك سيتم تزويدك بعبوة المداومة، والتي تحتوي على حقن ذات لون رمادي تحتوي على بليغريدي ١٢٥ ميكروغرام (لليوم الثامن والعشرين وبعد ذلك كل أسبوعين).</p><p dir="RTL">اقرأ هذه التعليمات في القسم رقم ٧ &quot; تعليمات عن كيفية الحقن بواسطة قلم الحقن بليغريدي المعبَّأ مُسبقًا&quot;، في نهاية هذه النشرة قبل البدء باستعمال دواء بليغريدي.</p><p dir="RTL">استعمال جدول التسجيل المطبوع على الوجه الداخلي من عبوة البدء للاحتفاظ بسجل لمواعيد الحقن الخاصة بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيامك بالحقن بنفسك</strong></p><p dir="RTL">يتعين حقن بليغريدي تحت جلد (الحقن تحت الجلد). قم بالتبديل بين المواضع التي تستخدمها للحقن. لا تستخدم نفس موضع الحقن لحقن متتالية.</p><p dir="RTL">يُمكنك حقن بليغريدي بنفسك بدون مساعدة من طبيبك؛ إذا كنت قد تلقيت تدريبًا على القيام بهذا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اقرأ واتَّبع النصيحة المُعطاة في التعليمات الواردة في القسم رقم ٧ &quot; تعليمات عن كيفية الحقن بواسطة قلم الحقن بليغريدي المعبَّأ مُسبقًا&quot; قبل البدء في الاستعمال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا واجهت مشكلة </strong>في التعامل مع الحقنة، اسأل طبيبك أو ممرضتك اللذان قد يكونا قادرين على مساعدتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي مدة استعمال بليغريدي</strong></p><p dir="RTL">سيُخبرك طبيبك عن المدة التي تحتاج خلالها للاستمرار في تناول بليغريدي. من المهم أن تستمر في استعمال بليغريدي بانتظام. لا تقم بتغييرات ما لم يخبرك طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تناول جرعة زائدة من بليغريدي</strong></p><p dir="RTL">يجب عليك حقن بليغريدي مرة كل أسبوعين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا استخدمت أكثر من حقنة واحدة من بليغريدي خلال فترة ٧ أيام؛ <strong>اتصل بطبيبك أو ممرضتك على الفور.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول جرعة بليغريدي</strong></p><p dir="RTL">أنت تحتاج لحقن بليغريدي مرة كل أسبوعين. هذا الجدول الزمني المنتظم يُساعد في تقديم العلاج على نحوٍ متساوٍ قدر الإمكان.</p><p dir="RTL">إذا فاتك تناول الجرعة في يومك المعتاد؛ فاحرص على تناولها في أقرب وقتٍ ممكن بالطريقة المعتادة.</p><p dir="RTL">ومع ذلك لا تستخدم أكثر من حقنة واحدة خلال فترة 7 أيام. لا تستخدم حقنتين للتعويض عن حقنة فائتة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك أسئلة أخرى حول استعمال هذا الدواء؛ اسأل طبيبك أو الصيدلي أو الممرضة.&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">مثل جميع الأدوية، فإن بليغريدي يسبب أعراضًا جانبية، على الرغم من أنه<strong> </strong>ليس<strong> </strong>ضروريًّا<strong> </strong>من<strong> </strong>أن يُعاني<strong> </strong>كل<strong> </strong>شخص<strong> </strong>منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية خطيرة</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل في الكبد</strong></p><p dir="RTL">(<em>شائعة</em> - قد <em>تؤثر على</em> ما يصل إلى 1 من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا واجهت أيًّا من هذه الأعراض:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد أو ابيضاض العينين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة في جميع أنحاء الجسم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء، والإصابة بالإعياء (الغثيان والتقيؤ).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سهولة الإصابة بكدمات الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اتصل </strong><strong>بالطبيب</strong><strong> </strong><strong>على الفور</strong>، فقد تكون أعراضًا لمشكلة مُحتملة في الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الاكتئاب</strong></p><p dir="RTL">(شائع - قد <em>تؤثر على</em> ما يصل إلى 1 من كل 10 أشخاص)</p><p dir="RTL">إذا واجهت أيًّا من هذه الأعراض:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالحزن أو القلق أو انعدام القيمة بصورة غير عادية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; راودتك أفكار حول الانتحار.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اتَّصل</strong><strong> </strong><strong>بالطبيب</strong><strong> على الفور.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>رد الفعل التحسسي الشديد</strong></p><p dir="RTL">(غير شائع - قد <em>يؤثر على</em> ما يصل إلى 1 من 100 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا واجهت أيًّا من هذه الأعراض:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفُّس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم حول الوجه (الشفتين، اللسان، أو الحلق).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح أو احمرار الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اتَّصل</strong><strong> </strong><strong>بالطبيب</strong><strong> على الفور.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>النوبات</strong></p><p dir="RTL">(غير <em>شائعة</em> - قد <em>تؤثر على</em> ما يصل إلى 1 من كل 100 شخص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كانت لديك نوبة أو تشنُّج؛ اتصل بطبيب على الفور.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تلف موقع الحقن</strong>.</p><p dir="RTL">(نادر - قد <em>يؤثر على</em> ما يصل إلى 1 من 1000 شخص)</p><p dir="RTL">إذا واجهت أيًّا من هذه الأعراض:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أي تشقق في الجلد مع تورم، أو التهاب، أو تسرُّب للسوائل حول موضع الحقن.&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اتصل </strong><strong>بالطبيب</strong><strong> </strong><strong>للحصول على المشورة.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مشاكل الكلى، بما في ذلك التندُّب، والذي قد يُقلل من الأداء الوظيفي للكلى</strong><strong> </strong><strong>لديك.</strong></p><p dir="RTL">(<em>نادرة</em> - قد <em>تؤثر على</em> ما يصل إلى 1 من 1000 شخص)</p><p dir="RTL">إذا واجهت أيًّا من الأعراض:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البول الرغوي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورُّم، خصوصًا في الكاحلين والجفون، وزيارة الوزن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اتصل </strong><strong>بالطبيب</strong><strong>؛ حيث إنها قد تكون علامات على مشكلة محتملة في الكلى.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل الدم</strong></p><p dir="RTL">(<em>نادرة</em> - قد <em>تؤثر على</em> ما يصل إلى 1 من كل 1000 شخص)</p><p dir="RTL">قد يحدث ما يلي: تكون جلطات دموية في الأوعية الدموية الصغيرة التي تُؤثر على كليتيك (الفرفرية القليلة الصفيحات الخثارية/ متلازمة انحلال الدم اليوريمي). قد تشمل الأعراض زيادة الكدمات، والنزيف، والحمى، والضعف الشديد، والصداع، والدوخة أو الدوار الخفيف. قد يجد طبيبك تغييرات في دمك ووظيفة كليتيك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا واجهت أيًّا من هذه أو كلًّا من هذه الأعراض:&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الكدمات أو النزيف.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الضعف الشديد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع، والدوخة أو الدوار.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اتَّصل</strong><strong> </strong><strong>بالطبيب</strong><strong> </strong><strong>على الفور.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض جانبية أخرى</strong></p><p dir="RTL"><strong>أعراض جانبية شائعة جدًّا</strong></p><p dir="RTL">(قد <em>تؤثر على</em> ما يصل إلى 1 من كل 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأعراض المشابهة للإنفلونزا. هذه الأعراض ليست إنفلونزا حقيقية، انظر أدناه. لا يُمكنك نقلها لأيِّ شخص آخر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في العضلات (<em>ألم</em> عضلي<em>).</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل، والذراعين، والساقين، أو الرقبة (<em>ألم</em> مفصلي<em>)</em>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف والتعب (الوهن<em>)</em>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار، أو الحكة، وألم حول موضع الحقن.&nbsp;&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا </strong><strong>أزعجتك</strong><strong> أيٌّ من هذه الأعراض؛ اتَّصل </strong><strong>بالطبيب</strong><strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض مشابهة للإنفلونزا</strong></p><p dir="RTL">الأعراض المشابهة للإنفلونزا تكون أكثر شيوعًا عند البدء باستعمال بليغريدي لأول مرة. وتقل تدريجيًّا مع الاستمرار في استعمال الحقن. انظر أدناه لمعرفة طرق بسيطة لإدارة هذه الأعراض المشابهة للإنفلونزا إذا واجهتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ثلاث طرق سهلة للمساعدة في تقليل تأثير الأعراض المشابهة للإنفلونزا:</p><p dir="RTL">1.&nbsp;&nbsp; &nbsp;ضع في اعتبارك توقيت حقنة بليغريدي. في المتوسط تختلف بداية الأعراض الشبيهة بالإنفلونزا ونهايتها من مريض لآخر. تبدأ الأعراض الشبيهة بالإنفلونزا بعد 10 ساعات تقريبًا من الحقن، وتستمر ما بين 12 و 24 ساعة.</p><p dir="RTL">2. &nbsp;&nbsp;&nbsp;تناول الباراسيتامول أو الإيبوبروفن قبل حقنة بليغريدي بنصف ساعة، واستمر في تناول الباراسيتامول أو الإيبوبروفين طوال مدة الأعراض الشبيهة بالإنفلونزا. تحدَّث إلى طبيبك أو الصيدلي حول المقدار الذي يجب أن تتناوله من العلاج والوقت الذي تستغرقه في العلاج.</p><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا أصبت بحمى؛ فاشرب الكثير من الماء للحفاظ على جسمك رطبًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض جانبية</strong><strong> </strong><strong>شائعة</strong></p><p dir="RTL">(قد <em>تؤثر على</em> ما يصل إلى 1 من 10 أشخاص)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور أو الإصابة بالإعياء (الغثيان والتقيؤ<em>)</em>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر (الصلع<em>)</em>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في الجلد (الحكة<em>)</em>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة درجة حرارة الجسم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في موضع الحقن مثل: التورم، أو الالتهاب، أو الكدمات، أو الدفء، أو الطفح الجلدي ، أو تغير اللون.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في دمك، والتي قد تسبب التعب أو تقلل القدرة على مكافحة الالتهاب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في إنزيمات الكبد في الدم (ستظهر في اختبارات الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا أزعجتك </strong><strong>أيٌّ</strong><strong> من هذه الأعراض؛ تحدث إلى طبيبك.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية</strong> <strong>غير شائعة</strong></p><p dir="RTL">(قد <em>تؤثر على</em> ما يصل إلى 1 من 100 <em>شخصٍ</em>)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات في دمك، والتي قد تسبب كدمات أو نزيف غير مبرر.&nbsp;&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا أزعجتك أيٌّ من هذه الأعراض؛ تحدث إلى طبيبك.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تكرار الأعراض غير معروف</strong></p><p dir="RTL"><strong>)</strong><em> لا يُمكن تقدير تكرار ظهور الأعراض من البيانات المتاحة</em><em> </em><em>(</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم الشرياني الرئوي: مرض تضييق الأوعية الدموية في الرئتين؛ ويؤدي إلى ارتفاع ضغط الدم في الأوعية الدموية التي تحمل الدم من القلب إلى الرئتين. كان ارتفاع ضغط الدم الشرياني الرئوي يظهر في نقاط زمنية مختلفة أثناء العلاج، بما في ذلك بعد سنوات من بدء العلاج بمنتجات بيتا إنترفيرون<strong>.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا واجهت أيًّا من هذه الأعراض؛ تحدث إلى طبيبك أو الصيدلي أو الممرضة. يشمل هذا أيَّ أعراض جانبية غير واردة في هذه النشرة. يُمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً &nbsp;عن طريق نظام الإبلاغ الوطني المُدرج في القسم ٦. من خلال الإبلاغ عن الأعراض الجانبية؛ يُمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">من أجل تحسين تتبُّع هذا الدواء؛ يجب على طبيبك أو الصيدلي تسجيل اسم ورقم التشغيلة للمنتج الذي قدمته في ملف المريض الخاص بك. قد ترغب أيضًا في تدوين هذه التفاصيل في حالة مطالبتك بهذه المعلومات في المستقبل.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ هذا الدواء بعيدًا عن متناول ومرآى الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم بليغريدي بعد تاريخ انتهاء الصلاحية المُدوَّن على عبوة الكرتون والمُلصق بعد &quot;EXP&quot;. &nbsp;تاريخ انتهاء الصلاحية يشير إلى آخر يوم في ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ ببليغريدي في علبته الأصلية من أجل حمايته من الضوء. افتح العبوة فقط عندما تحتاج لحقنة جديدة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قم بتخزينه في الثلاجة،</strong> )الثلاجة( 2 -8 مئوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقم بتجميد الدواء. تخلَّص من أيِّ دواء بليغريدي قد تم تجميده عن طريق الخطأ.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكن الاحتفاظ ببليغريدي خارج الثلاجة، في درجة حرارة الغرفة (ما يصل إلى 30 درجة مئوية) ولمدة تصل إلى 7 أيام، ولكن يجب أن يُحفظ <strong>بعيدًا عن الضوء.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكن إخراج العبوات من الثلاجة ثم إعادة وضعها في الثلاجة أكثر من مرة عند الضرورة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تأكَّد من عدم بقاء الحقن خارج الثلاجة <strong>لأكثر من 7 أيام في المجموع.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخلَّص من أيِّ حقن احتُفظ بها خارج الثلاجة<strong> لأكثر من 7 أيام</strong><strong>.</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت غير متأكد من عدد الأيام التي احتفظت بالحقنة خلالها خارج الثلاجة؛ فتخلص منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء إذا لاحظت أيًّا مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان القلم مكسورًا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كان المحلول ملونًا، أو عكرًا، أو استطعت رؤية جسيمات عائمة فيه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي التخلُّص من أيِّ أدوية عن طريق مياه الصرف، أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه حول كيفية التخلُّص من الأدوية التي لم تعد تستعملها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ما هي محتويات بليغريدي</strong></p><p dir="RTL">المادة الفعالة هي: بيغ إنترفيرون بيتا 1أ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كل حقنة 63 ميكروغرام معبأة مسبقًا بشكل قلم تحتوي على 63 ميكروغرام من البيغ إنترفيرون بيتا 1أ في محلول 0.5 مليلتر للحقن.</p><p dir="RTL">كل حقنة 94 ميكروغرام معبأة مسبقًا بشكل قلم تحتوي على 94 ميكروغرام من البيغ إنترفيرون بيتا 1أ في محلول 0.5 مليلتر للحقن.</p><p dir="RTL">كل حقنة 125 ميكروغرام معبأة مسبقًا بشكل قلم تحتوي على &nbsp;125ميكروغرام من البيغ إنترفيرون بيتا 1أ في محلول 0.5 مليلتر للحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي: صوديوم اسيتات تريهيدرات، أسيتك أسيد، غلاسيال، أرجينين الهيدروكلورايد، البوليسوربات 20، وماء للحقن.&nbsp;&nbsp; )انظر القسم ٢ بليغريدي يحتوي على الصوديوم(</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هو الشكل الصيدلاني لـ بليغريدي ومحتويات العبوة&nbsp; &nbsp;</strong></p><p dir="RTL">بليغريدي هو محلول شفاف بلا لون محلول للحقن بشكل قلم معبأ مسبقًا مع إبرة مُرفقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحجام العبوات:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عبوة البدء لدواء بليغريدي تحتوي على حقنة برتقالية معبأة مسبقًا بشكل قلم تحتوي على 63 ميكروغرام وواحدة أخرى زرقاء تحتوي على 94 ميكروغرام.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحقنة الرمادية التي تحتوي على 125 ميكروغرام يتم توفيرها في عبوة تحتوي على حقنتين معبأتين مسبقًا في شكل أقلام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مالك حق التسويق</strong><strong> </strong><strong>(المسؤول عن تحرير الصنف)</strong></p><p dir="RTL">Biogen Netherlands B.V</p><p dir="RTL">Prins Mauritslaan 13</p><p dir="RTL">1171 LP Badhoevedorp</p><p dir="RTL">The Netherlands</p><p dir="RTL">هولندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مصنع الشكل الصيدلاني</strong></p><p dir="RTL">Vetter Pharma- Fertigung GmbH &amp;Co. KG</p><p dir="RTL">Sch&uuml;tzenstrasse 87 and 99 - 101</p><p dir="RTL">88212 Ravensburg</p><p dir="RTL">Germany</p><p dir="RTL">ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
              06/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Plegridy 63 micrograms solution for injection in pre filled pen
Plegridy 94 micrograms solution for injection in pre filled pen
Plegridy 125  micrograms solution for injection in pre filled pen

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Plegridy 63 micrograms solution for injection in pre filled pen 
Each pre filled pen contains 63 micrograms of peginterferon beta 1a* in 0.5 mL solution for injection.

Plegridy 94 micrograms solution for injection in pre filled pen 
Each pre filled pen contains 94 micrograms of peginterferon beta 1a* in 0.5 mL solution for injection.

Plegridy 125 micrograms solution for injection in pre filled pen 
Each pre filled pen contains 125 micrograms of peginterferon beta 1a* in 0.5 mL solution for injection.

The dose indicates the quantity of the interferon beta 1a moiety of peginterferon beta 1a without consideration of the PEG moiety attached.
*The active substance, peginterferon beta 1a, is a covalent conjugate of interferon beta 1a, produced in Chinese hamster ovary cells, with 20,000 Dalton (20 kDa) methoxy poly(ethyleneglycol) using an O 2 methylpropionaldehyde linker.

The potency of this medicinal product should not be compared to the one of another pegylated or non pegylated protein of the same therapeutic class. For more information see section 5.1.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Solution for injection (injection).

Clear and colourless solution with pH 4.5-5.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Plegridy is indicated in adult patients for the treatment of relapsing remitting multiple sclerosis (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Treatment should be initiated under supervision of a physician experienced in the treatment of multiple sclerosis.</p><p>&nbsp;</p><p>Efficacy of peginterferon beta‑1a<strong> </strong>has been demonstrated over placebo. Direct comparative data for peginterferon beta‑1a<strong> </strong>versus non‑pegylated interferon beta or data on efficacy of peginterferon beta‑1a<strong> </strong>after switching from a non-pegylated interferon beta are not available. This should be considered when switching patients between pegylated and non‑pegylated interferons (see section 5.1).</p><p>&nbsp;</p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p>The recommended dose of Plegridy is 125&nbsp;micrograms injected subcutaneously every 2&nbsp;weeks (14 days).</p><p>&nbsp;</p><p><em>Treatment initiation </em></p><p><u>&nbsp;</u></p><p>It is generally recommended that patients start treatment with 63&nbsp;micrograms at dose&nbsp;1 (on day 0), increasing to 94&nbsp;micrograms at dose&nbsp;2 (on day 14), reaching the full dose of 125&nbsp;micrograms by dose&nbsp;3 (on day 28) and continuing with the full dose (125&nbsp;micrograms) every 2&nbsp;weeks (14 days) thereafter (see Table 1). An initiation pack is available containing the first 2 doses (63&nbsp;micrograms and 94&nbsp;micrograms).</p><p>&nbsp;</p><p>Table 1: Titration schedule at initiation</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Dose</p></td><td style="vertical-align:top"><p>Time*</p></td><td style="vertical-align:top"><p>Amount (micrograms)</p></td><td style="vertical-align:top"><p>Pen label</p></td></tr><tr><td style="vertical-align:top"><p>Dose&nbsp;1</p></td><td style="vertical-align:top"><p>Day&nbsp;0</p></td><td style="vertical-align:top"><p>63</p></td><td style="vertical-align:top"><p>Orange</p></td></tr><tr><td style="vertical-align:top"><p>Dose&nbsp;2</p></td><td style="vertical-align:top"><p>Day 14</p></td><td style="vertical-align:top"><p>94</p></td><td style="vertical-align:top"><p>Blue</p></td></tr><tr><td style="vertical-align:top"><p>Dose&nbsp;3</p></td><td style="vertical-align:top"><p>Day 28</p></td><td style="vertical-align:top"><p>125 (full dose)</p></td><td style="vertical-align:top"><p>Grey</p></td></tr></tbody></table><p>*Dosed every 2&nbsp;weeks (14 days)</p><p>&nbsp;</p><p>Dose titration at the initiation of treatment may help to ameliorate flu‑like symptoms that can occur at treatment initiation with interferons. Prophylactic and concurrent use of anti‑inflammatory, analgesic and/or antipyretic treatments may prevent or ameliorate flu‑like symptoms sometimes experienced during interferon treatment (see section 4.8).</p><p>&nbsp;</p><p>If a dose is missed, it should be administered as soon as possible.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If 7&nbsp;days or more to the next planned dose: Patients should administer their missed dose immediately. Treatment can then continue with the next scheduled dose as planned.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If less than 7&nbsp;days to the next planned dose: Patients should begin a new 2&nbsp;week dosing schedule starting from when they administer their missed dose. A patient should not administer two doses of peginterferon beta‑1a<strong> </strong>within 7&nbsp;days of each other.</p><p>&nbsp;</p><p><u>Special populations </u></p><p>&nbsp;</p><p><em>Elderly population</em></p><p><u>&nbsp;</u></p><p>The safety and efficacy of peginterferon beta‑1a<strong> </strong>in patients over the age of 65&nbsp;have not been sufficiently studied due to the limited number of such patients included in clinical trials.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p><u>&nbsp;</u></p><p>No dosage adjustments are necessary in patients with renal impairment based on study data in mild, moderate, and severe renal impairment and end stage renal disease (see sections 4.4 and 5.2).&nbsp;</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p><u>&nbsp;</u></p><p>Peginterferon beta‑1a<strong> </strong>has not been studied in patients with hepatic impairment (see section 4.4).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><u>&nbsp;</u></p><p>The safety and efficacy of peginterferon beta‑1a<strong> </strong>in children and adolescents aged 0&nbsp;to 18&nbsp;years have not been established in multiple sclerosis. No data are available.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p><u>&nbsp;</u></p><p>Plegridy is for subcutaneous use.</p><p><u>&nbsp;</u></p><p>It is recommended that a healthcare professional trains patients in the proper technique for self‑administering subcutaneous injections using the pre‑filled pen. Patients should be advised to rotate sites for subcutaneous injections every 2 weeks. The usual sites for subcutaneous injections include abdomen, arm, and thigh.</p><p>&nbsp;</p><p>Pre‑filled pens are for single use only and should be discarded after use.</p><p>&nbsp;</p><p><em>Precautions to be taken before handling or administering the medicinal product</em></p><p>&nbsp;</p><p>Once removed from the refrigerator, Plegridy should be allowed to warm to room temperature (up to 30&deg;C) for about 30&nbsp;minutes prior to injection. External heat sources such as hot water must not be used to warm the medicinal product.</p><p>&nbsp;</p><p>Plegridy pre‑filled pen must not be used unless the green stripes are visible in the pen injection status window. Plegridy pre‑filled pen must not be used if the liquid is coloured, cloudy, or contains floating particles. The liquid in the medicinal product window must be clear and colourless.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to natural or recombinant interferon beta or peginterferon or to any of the excipients listed in section 6.1.
-	Patients with current severe depression and/or suicidal ideation (see sections 4.4 and 4.8).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number</p><p>of the administered product should be clearly recorded.</p><p><u>&nbsp;</u></p><p><u>Hepatic injury </u></p><p><u>&nbsp;</u></p><p>Elevated serum hepatic transaminase levels, hepatitis, autoimmune hepatitis and rare cases of severe hepatic failure have been reported with interferon beta medicinal products. Elevations in hepatic enzymes and noninfectious hepatitis have been observed with the use of peginterferon beta‑1a. Patients should be monitored for signs of hepatic injury (see section 4.8).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Depression</u></p><p><u>&nbsp;</u></p><p>Peginterferon beta‑1a<strong> </strong>should be administered with caution to patients with previous depressive disorders (see section 4.3). Depression occurs with increased frequency in the multiple sclerosis population and in association with interferon use. Patients should be advised to immediately report any symptoms of depression and/or suicidal ideation to their prescribing physician.</p><p>&nbsp;</p><p>Patients exhibiting depression should be monitored closely during therapy and treated appropriately. Cessation of therapy with peginterferon beta‑1a<strong> </strong>should be considered (see section 4.8).</p><p>&nbsp;</p><p><u>Hypersensitivity reactions</u></p><p><u>&nbsp;</u></p><p>Serious hypersensitivity reactions including cases of anaphylaxis have been reported as a rare complication of treatment with interferon beta, including peginterferon beta‑1a. Patients should be advised to discontinue treatment with peginterferon beta‑1a<strong> </strong>and seek immediate medical care if they experience signs and symptoms of anaphylaxis or severe hypersensitivity. Treatment with peginterferon beta‑1a<strong> </strong>should not be restarted (see section 4.8).<u> </u></p><p><u>&nbsp;</u></p><p><u>Injection site reactions</u></p><p><u>&nbsp;</u></p><p>Injection site reactions, including injection site necrosis, have been reported with the use of subcutaneous interferon beta. To minimise the risk of injection site reactions patients should be instructed in the use of an aseptic injection technique. The procedure for the self‑administration by the patient should be reviewed periodically especially if injection site reactions have occurred. If the patient experiences any break in the skin, which may be accompanied by swelling or drainage of fluid from the injection site, the patient should be advised to speak with their doctor. One patient treated with peginterferon beta‑1a<strong> </strong>in clinical trials experienced an injection site necrosis. Whether to discontinue therapy following a single site of necrosis is dependent on the extent of necrosis (see section 4.8).</p><p>&nbsp;</p><p><u>Decreased peripheral blood counts</u></p><p><u>&nbsp;</u></p><p>Decreased peripheral blood counts in all cell lines, including rare pancytopenia and severe thrombocytopenia, have been reported in patients receiving interferon beta. Cytopenias, including rare severe neutropenia and thrombocytopenia, have been observed in patients treated with peginterferon beta‑1a. Patients should be monitored for symptoms or signs of decreased peripheral blood counts (see section 4.8).</p><p><u>&nbsp;</u></p><p><u>Renal and urinary disorders </u></p><p><u>&nbsp;</u></p><p><em>Nephrotic syndrome (class effects)</em></p><p>&nbsp;</p><p>Cases of nephrotic syndrome with different underlying nephropathies including collapsing focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), membranoproliferative glomerulonephritis (MPGN) and membranous glomerulopathy (MGN) have been reported during treatment with interferon‑beta products. Events were reported at various time points during treatment and may occur after several years of treatment with interferon beta. Periodic monitoring of early signs or symptoms, e.g. oedema, proteinuria and impaired renal function is recommended, especially in patients at higher risk of renal disease. Prompt treatment of nephrotic syndrome is required and discontinuation of treatment with peginterferon beta‑1a<strong> </strong>should be considered.</p><p>&nbsp;</p><p><em>Severe renal impairment</em></p><p>&nbsp;</p><p>Caution should be used when administering peginterferon beta‑1a<strong> </strong>to patients with severe renal impairment.</p><p>&nbsp;</p><p><u>Thrombotic microangiopathy (TMA) (class effects)</u></p><p><u>&nbsp;</u></p><p>Cases of TMA, manifested as thrombotic thrombocytopenic purpura (TTP) or haemolytic uraemic syndrome (HUS), including fatal cases, have been reported with interferon beta products. Events were reported at various time points during treatment and may occur several weeks to several years after starting treatment with interferon beta. Early clinical features include thrombocytopenia, new onset hypertension, fever, central nervous system symptoms (e.g. confusion, paresis) and impaired renal function. Laboratory findings suggestive of TMA include decreased platelet counts, increased serum lactate dehydrogenase (LDH) due to haemolysis and schistocytes (erythrocyte fragmentation) on a blood film. Therefore if clinical features of TMA are observed, further testing of blood platelet levels, serum LDH, blood films and renal function is recommended. If TMA is diagnosed, prompt treatment is required (considering plasma exchange) and immediate discontinuation of peginterferon beta‑1a<strong> </strong>is recommended.</p><p><u>&nbsp;</u></p><p><u>Laboratory abnormalities</u></p><p><u>&nbsp;</u></p><p>Laboratory abnormalities are associated with the use of interferons. In addition to those laboratory tests normally required for monitoring patients with multiple sclerosis, complete blood and differential blood cell counts, platelet counts, and blood chemistries, including liver function tests (e.g. aspartate aminotransferase (AST), alanine aminotransaminase (ALT)), are recommended prior to initiation and at regular intervals following introduction of peginterferon beta‑1a<strong> </strong>therapy and then periodically thereafter in the absence of clinical symptoms.</p><p>&nbsp;</p><p>Patients with myelosuppression may require more intensive monitoring of complete blood cell counts, with differential and platelet counts.<br /><br />Hypothyroidism and hyperthyroidism have been observed with the use of interferon beta products. Regular thyroid function tests are recommended in patients with a history of thyroid dysfunction or as clinically indicated.</p><p>&nbsp;</p><p><u>Seizure</u></p><p><u>&nbsp;</u></p><p>Peginterferon beta‑1a<strong> </strong>should be administered with caution to patients with a history of seizures, to those receiving treatment with anti‑epileptics, particularly if their epilepsy is not adequately controlled with anti‑epileptics (see section 4.8).</p><p>&nbsp;</p><p><u>Cardiac disease</u></p><p><u>&nbsp;</u></p><p>Worsening of cardiac disease has been reported in patients receiving interferon beta. The incidence of cardiovascular events was similar between peginterferon beta‑1a<strong> </strong>(125&nbsp;micrograms every 2&nbsp;weeks) and placebo treatment groups (7% in each group). No serious cardiovascular events were reported in patients who received peginterferon beta‑1a<strong> </strong>in the ADVANCE study.&nbsp; Nevertheless, patients with pre‑existing significant cardiac disease, such as congestive heart failure, coronary artery disease or arrhythmia should be monitored for worsening of their cardiac condition, particularly during initiation of treatment.&nbsp;</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p><u>&nbsp;</u></p><p>Patients may develop antibodies to peginterferon beta‑1a. Data from patients treated up to 2&nbsp;years with peginterferon beta‑1a<strong> </strong>suggests that less than 1% (5/715) developed persistent‑neutralising antibodies to the interferon beta‑1a portion of peginterferon beta-1a. Neutralising antibodies have the potential to reduce clinical efficacy. However, the development of antibodies against the interferon moiety of peginterferon beta‑1a had no discernible impact on safety or clinical efficacy, although the analysis was limited by the low immunogenicity incidence.</p><p>&nbsp;</p><p>Three percent of patients (18/681) developed persistent antibodies to the PEG moiety of peginterferon beta‑1a.&nbsp; In the clinical study conducted, the development of antibodies against the PEG moiety of peginterferon beta‑1a had no discernible impact on safety, or clinical efficacy (including annualised relapse rate, magnetic resonance imaging (MRI) lesions, and disability progression).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>&nbsp;</p><p>Caution should be used and close monitoring considered when administering peginterferon beta‑1ato patients with severe hepatic impairment. Patients should be monitored for signs of hepatic injury and caution exercised when interferons are used concomitantly with other medicinal products associated with hepatic injury (see sections 4.8 and 5.2).</p><p>&nbsp;</p><p><u>Sodium content</u></p><p><u>&nbsp;</u></p><p>This medicinal product contains less than 1&nbsp;mmol (23&nbsp;mg) sodium, that is to say it is essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed. The clinical studies indicate that multiple sclerosis patients can receive peginterferon beta‑1a and corticosteroids during relapses. Interferons have been reported to reduce the activity of hepatic cytochrome P450‑dependent enzymes in humans and animals. Caution should be exercised when peginterferon beta‑1a is administered in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system for clearance, e.g. some classes of antiepileptics and antidepressants.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p>A large amount of data (more than 1000 pregnancy outcomes) from registries and post-marketing experience indicates no increased risk of major congenital anomalies after pre-conception exposure to interferon beta or such exposure during the first trimester of pregnancy. However, the duration of exposure during the first trimester is uncertain, because data were collected when interferon beta use was contraindicated during pregnancy, and treatment likely interrupted when pregnancy was detected and/or confirmed. Experience with exposure during the second and third trimester is very limited.</p><p>&nbsp;</p><p>Based on animal data (see section 5.3), there is a possibly increased risk for spontaneous abortion.&nbsp; The risk of spontaneous abortions in pregnant women exposed to interferon beta cannot adequately be evaluated based on the currently available data, but the data do not suggest an increased risk so far.</p><p>&nbsp;</p><p>If clinically needed, the use of peginterferon beta‑1a may be considered during pregnancy.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p><u>&nbsp;</u></p><p>It is not known whether peginterferon beta-1a is secreted in human milk. Limited information available on the transfer of interferon beta-1a into breast milk, together with the chemical / physiological characteristics of interferon beta, suggests that levels of interferon beta-1a excreted in human milk are negligible. No harmful effects on the breastfed newborn/infant are anticipated.</p><p>&nbsp;</p><p>Peginterferon beta‑1a can be used during breast-feeding.</p><p><em>&nbsp;</em></p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>There are no data on the effects of peginterferon beta-1a on human fertility.&nbsp; In animals, anovulatory effects were observed at very high doses (see section 5.3).&nbsp; No information is available on the effects of peginterferon beta-1a on male fertility in animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Peginterferon beta‑1a has no or negligible influence on the ability to drive and use machines.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>&nbsp;</p><p>The most common adverse drug reactions (ADR) (at a higher incidence than placebo) for peginterferon beta‑1a 125&nbsp;micrograms subcutaneously every 2&nbsp;weeks were injection site erythema, influenza like illness, pyrexia, headache, myalgia, chills, injection site pain, asthenia, injection site pruritus, and arthralgia.</p><p>The most commonly reported adverse reaction leading to discontinuation in patients treated with peginterferon beta‑1a 125&nbsp;micrograms subcutaneously every 2&nbsp;weeks was influenza-like illness (&lt;1%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>In clinical studies, a total of 1468&nbsp;patients received peginterferon beta‑1a for up to 278&nbsp;weeks with an overall exposure equivalent of 4217&nbsp;person‑years.&nbsp;1285&nbsp;patients received at least 1&nbsp;year,&nbsp;1124 patients have received at least 2&nbsp;years, 947&nbsp;patients received at least 3&nbsp;years, and 658&nbsp;patients received at least 4&nbsp;years of treatment with peginterferon beta‑1a. The experience in the randomised, uncontrolled phase (year&nbsp;2) of the ADVANCE study and in the extension study ATTAIN (treatment received for up to 4&nbsp;years) was consistent with the experience in the 1&nbsp;year placebo-controlled phase of the ADVANCE study.</p><p>&nbsp;</p><p>Table 2 summarizes ADRs (incidence above placebo and with a reasonable possibility of causality) from 512&nbsp;patients treated with peginterferon beta‑1a 125&nbsp;micrograms subcutaneously every 2&nbsp;weeks and 500&nbsp;patients who received placebo for up to 48&nbsp;weeks and post-marketing data.</p><p>&nbsp;</p><p>The ADRs are presented as MedDRA preferred terms under the MedDRA System Organ Class. The incidence of the adverse reactions below are expressed according to the following categories:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common (&ge;1/10)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common (&ge;1/100 to &lt;1/10)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon (&ge;1/1, 000 to &lt;1/100)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare (&ge;1/10, 000 to &lt;1/1,000)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rare (&lt;1/10,000)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not known (cannot be estimated from the available data)</p><p>&nbsp;</p><p><strong>Table 2 Tabulated summary of adverse drug reactions</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td></tr></thead><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Thrombotic microangiopathy including thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome*</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Angioedema</p></td><td rowspan="2" style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity &nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylaxis<strong><sup>1</sup></strong></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Seizure</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Pulmonary arterial hypertension<sup>┼</sup></p></td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea</p></td><td rowspan="2" style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Hepatitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Alopecia<sup>$</sup></p></td><td rowspan="2" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td rowspan="2" style="vertical-align:top"><p>Very common</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Nephrotic syndrome, glomerulosclerosis</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="16" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Influenza like illness</p></td><td rowspan="7" style="vertical-align:top"><p>Very common</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>Chills</p></td></tr><tr><td style="vertical-align:top"><p>Injection site erythema</p></td></tr><tr><td style="vertical-align:top"><p>Injection site pain</p></td></tr><tr><td style="vertical-align:top"><p>Injection site pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia</p></td></tr><tr><td style="vertical-align:top"><p>Hyperthermia</p></td><td rowspan="9" style="vertical-align:top"><p>Common</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection site inflammation</p></td></tr><tr><td style="vertical-align:top"><p>Pain</p></td></tr><tr><td style="vertical-align:top"><p>Injection site haematoma</p></td></tr><tr><td style="vertical-align:top"><p>Injection site swelling</p></td></tr><tr><td style="vertical-align:top"><p>Injection site oedema</p></td></tr><tr><td style="vertical-align:top"><p>Injection site rash</p></td></tr><tr><td style="vertical-align:top"><p>Injection site warmth</p></td></tr><tr><td style="vertical-align:top"><p>Injection site discolouration</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Injection site necrosis</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td rowspan="6" style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td></tr><tr><td style="vertical-align:top"><p>Gamma-glutamyltransferase increased</p></td></tr><tr><td style="vertical-align:top"><p>White blood cell count decreased</p></td></tr><tr><td style="vertical-align:top"><p>Haemoglobin decreased</p></td></tr><tr><td style="vertical-align:top"><p>Body temperature increased</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Platelet count decreased</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p>*Class label for interferon beta products (see section 4.4).</p><p><sup>┼</sup> Class label for interferon products, see below <em>Pulmonary arterial hypertension</em></p><p><sup>$ </sup>Class label for interferon products</p><p><strong><sup>1 </sup></strong>Adverse reactions derived only during post marketing experience</p><p><strong>&nbsp;</strong></p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em>Flu‑like symptoms</em></p><p><u>&nbsp;</u></p><p>Influenza‑like illness was experienced by 47% of patients receiving peginterferon beta‑1a 125&nbsp;micrograms every 2&nbsp;weeks and 13% of patients receiving placebo. The incidence of flu‑like symptoms (e.g. influenza‑like illness, chills, hyperpyrexia, musculoskeletal pain, myalgia, pain, pyrexia) was highest at the initiation of treatment and generally decreased over the first 6&nbsp;months. Of the patients who reported flu-like symptoms 90% reported them as mild or moderate in severity. None were considered serious in nature. Less than 1% of patients who received peginterferon beta‑1a during the placebo-controlled phase of the ADVANCE study discontinued treatment due to flu‑like symptoms. An open‑label study in patients switching from interferon beta therapy to peginterferon beta‑1a evaluated the onset and duration of prophylactically treated flu‑like symptoms. In patients experiencing flu‑like symptoms, the median time to onset was 10&nbsp;hours (interquartile range, 7&nbsp;to 16&nbsp;hours) after injection, and the median duration was 17&nbsp;hours (interquartile range, 12&nbsp;to 22&nbsp;hours).</p><p>&nbsp;</p><p><em>Injection site reactions (ISRs)</em></p><p><u>&nbsp;</u></p><p>ISRs (e.g. injection site erythema, pain, pruritus, or oedema) were reported by 66% of patients who received peginterferon beta‑1a 125&nbsp;micrograms every 2&nbsp;weeks compared to 11% of patients receiving placebo. Injection site erythema was the most commonly reported injection site reaction. Of the patients who experienced injection site reactions 95% reported them as mild or moderate in severity. One patient out of 1468&nbsp;patients who received peginterferon beta‑1a in clinical studies experienced an injection site necrosis which resolved with standard medical treatment.</p><p>&nbsp;</p><p><em>Hepatic transaminase abnormalities</em></p><p><u>&nbsp;</u></p><p>The incidence of hepatic transaminase increases was greater in patients receiving peginterferon beta‑1a compared to placebo. The majority of enzyme elevations were &lt;3&nbsp;times the upper limit of normal (ULN). Elevations of alanine aminotransferase and aspartate aminotransferase (&gt;5&nbsp;times ULN), were reported in 1% and &lt;1% of placebo-treated patients and 2% and &lt;1% of patients treated with peginterferon beta‑1a respectively. Elevations of serum hepatic transaminases combined with elevated bilirubin were observed in two patients who had pre‑existing liver test abnormalities prior to receiving peginterferon beta‑1a in the clinical trials. Both cases resolved following discontinuation of the medicinal product.</p><p>&nbsp;</p><p><em>Hepatitis</em></p><p><em>&nbsp;</em></p><p>In post marketing experience, noninfectious hepatitis (including serious hepatitis) cases have been reported following Plegridy administration (see 4.4 Section <u>Hepatic injury</u>).</p><p>&nbsp;</p><p><em>Haematological disorders</em></p><p><u>&nbsp;</u></p><p>Decreases in white blood cell counts (WBC) of &lt;3.0&nbsp;x&nbsp;10<sup>9</sup>/L were observed in 7% of patients receiving peginterferon beta‑1a and in 1% receiving placebo. Mean WBC counts remained within normal limits in patients treated with peginterferon beta‑1a. Decreases in WBC counts were not associated with an increased risk of infections or serious infections. The incidence of potentially clinically significant decreases in lymphocyte counts (&lt;0.5&nbsp;x&nbsp;10<sup>9</sup>/L) (&lt;1%), neutrophil counts (&le;1.0&nbsp;x&nbsp;10<sup>9</sup>/L) (&lt;1%) and platelet counts (&le;100&nbsp;x&nbsp;10<sup>9</sup>/L) (&le;1%) was similar in peginterferon beta‑1a-treated patients compared to placebo-treated patients. Two serious cases were reported in patients treated with peginterferon beta‑1a: one patient (&lt;1%) experienced severe thrombocytopenia (platelet count &lt;10&nbsp;x&nbsp;10<sup>9</sup>/L), another patient (&lt;1%) experienced severe neutropenia (neutrophil count &lt;0.5&nbsp;x&nbsp;10<sup>9</sup>/L). In both patients, cell counts recovered after discontinuation of peginterferon beta‑1a. Slight decreases in mean red blood cell (RBC) counts were observed in peginterferon beta‑1a treated patients. The incidence of potentially clinically significant decreases in RBC counts (&lt;3.3&nbsp;x&nbsp;10<sup>12</sup>/L) was similar in peginterferon beta‑1a‑treated patients compared to placebo‑treated patients.</p><p>&nbsp;</p><p><em>Hypersensitivity reactions</em></p><p><u>&nbsp;</u></p><p>Hypersensitivity events were reported in 16% of patients treated with peginterferon beta‑1a 125&nbsp;micrograms every 2&nbsp;weeks and 14% of patients who received placebo. Less than 1% of peginterferon beta‑1a treated patients experienced a serious hypersensitivity event (e.g. angioedema, urticaria) and they recovered promptly after treatment with anti-histamines and/or corticosteroids. In post marketing experience, serious hypersensitivity events including cases of anaphylaxis (frequency not known) have been reported following peginterferon beta‑1a administration.</p><p>&nbsp;</p><p><em>Pulmonary arterial hypertension</em></p><p><em>&nbsp;</em></p><p>Cases of pulmonary arterial hypertension (PAH) have been reported with interferon beta products. Events were reported at various time points including up to several years after starting treatment with interferon beta.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system detailed below.</p><p><strong>&nbsp;</strong></p><p><strong><u>Please report adverse drug events to:</u></strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax&nbsp;: +966-11-205-7662</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Other GCC states:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;In case of over-dose, patients may be hospitalized for observation and appropriate supportive treatment should be given.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pharmacotherapeutic group: Antineoplastic and immunomodulating agents, immunostimulants, interferons, ATC code: L03AB13</p><p>&nbsp;</p><p>Peginterferon beta‑1a is an interferon beta‑1a conjugated with a single, linear molecule of 20,000&nbsp;Da methoxy poly(ethyleneglycol)‑O‑2‑methylpropionaldehyde (20&nbsp;kDa mPEG‑O‑2‑methylpropionaldehyde) at a degree of substitution of 1&nbsp;mole of polymer/mole of protein. The average molecular mass is approximately 44&nbsp;kDa of which the protein moiety constitutes approximately 23&nbsp;kDa.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>A definitive mechanism of action of peginterferon beta-1a in multiple sclerosis (MS) is not known. peginterferon beta‑1a binds to the type I interferon receptor on the surface of cells and elicits a cascade of intracellular events leading to the regulation of interferon-responsive gene expression. Biological effects that may be mediated by peginterferon beta‑1a include up-regulation of anti-inflammatory cytokines (e.g. IL‑4, IL‑10, IL‑27), down-regulation of pro-inflammatory cytokines (e.g. IL‑2, IL‑12, IFN‑&gamma;, TNF‑&alpha;) and inhibiting the migration of activated T cells across the blood brain barrier; however additional mechanisms may be involved. Whether the mechanism of action of peginterferon beta‑1a in MS is mediated by the same pathway(s) as the biological effects described above is not known because the pathophysiology of MS is only partially understood.</p><p><u>&nbsp;</u></p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p>Peginterferon beta‑1a is interferon beta-1a conjugated to a single, linear 20&nbsp;kDa methoxy poly(ethyleneglycol) molecule at the alpha-amino group of the N‑terminal amino acid residue.</p><p>&nbsp;</p><p>Interferons are a family of naturally occurring proteins that are induced by cells in response to biological and chemical stimuli, and mediate numerous cellular responses that have been classified as antiviral, antiproliferative, and immunomodulatory in nature. &nbsp;The pharmacological properties of peginterferon beta‑1a are consistent with those of interferon beta‑1a and are believed to be mediated by the protein portion of the molecule.</p><p>&nbsp;</p><p>Pharmacodynamic responses were evaluated by measuring the induction of interferon-responsive genes including those encoding 2&prime;,5&prime;‑oligoadenylate synthetase (2&prime;,5&prime;‑OAS), myxovirus resistance protein A (MxA), and several chemokines and cytokines, as well as neopterin (D‑erythro‑1, 2, 3,-trihydroxypropylpterin), a product of the interferon-inducible enzyme, GTP‑cyclohydrolase I. Gene induction in healthy human subjects was greater in terms of peak level and exposure (area under the effect curve) for peginterferon beta‑1a compared to non‑pegylated interferon beta‑1a (IM) when both were given at the same dose by activity (6&nbsp;MIU). The duration of this response was sustained and prolonged for peginterferon beta‑1a, with elevations detected up to 15&nbsp;days compared to 4&nbsp;days for non‑pegylated interferon beta‑1a. Increased concentrations of neopterin were observed in both healthy subjects and multiple sclerosis patients treated with peginterferon beta‑1a, with a sustained and prolonged elevation over 10&nbsp;days compared to 5&nbsp;days observed for non‑pegylated interferon beta‑1a. Neopterin concentrations return to baseline after the two week dosing interval.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p>The efficacy and safety of peginterferon beta‑1a was assessed from the placebo‑controlled first year of a 2&nbsp;year randomised, double-blind, clinical study in patients with relapsing remitting multiple sclerosis (the ADVANCE study). 1512&nbsp;patients were randomised to and dosed with 125&nbsp;micrograms peginterferon beta‑1a injected subcutaneously every 2&nbsp;(n=512) or 4&nbsp;(n=500) weeks versus placebo (n=500).</p><p>&nbsp;</p><p>The primary endpoint was the annualised relapse rate (ARR) over 1&nbsp;year. The study design and patient demographics are presented in Table&nbsp;3.</p><p>&nbsp;</p><p>No data are available from clinical efficacy/safety studies directly comparing pegylated with non‑pegylated interferon beta-1a, or from patients switching between non-pegylated and pegylated interferon.</p><p>&nbsp;</p><p>Table 3: Study design</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Study design</p></td></tr><tr><td style="vertical-align:top"><p>Disease history</p></td><td style="vertical-align:top"><p>Patients with RRMS, with at least 2&nbsp;relapses within the prior 3&nbsp;years, and 1 relapse in the prior year, with an EDSS score of &le;5.0</p></td></tr><tr><td style="vertical-align:top"><p>Follow-up</p></td><td style="vertical-align:top"><p>1&nbsp;year</p></td></tr><tr><td style="vertical-align:top"><p>Study population</p></td><td style="vertical-align:top"><p>83% treatment-na&iuml;ve patients</p><p>47% &ge;2 relapses in prior year</p><p>38% at least 1 Gd+ lesion at baseline</p><p>92% &ge;9 T2 lesions baseline</p><p>16% EDSS &ge;4</p><p>17% previously treated</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Baseline characteristics</p></td></tr><tr><td style="vertical-align:top"><p>Mean age (years)</p></td><td style="vertical-align:top"><p>37</p></td></tr><tr><td style="vertical-align:top"><p>Mean/Median disease duration (years)</p></td><td style="vertical-align:top"><p>3.6/2.0</p></td></tr><tr><td style="vertical-align:top"><p>Mean number of relapses within the past 3 years</p></td><td style="vertical-align:top"><p>2.5</p></td></tr><tr><td style="vertical-align:top"><p>Mean EDSS score at baseline</p></td><td style="vertical-align:top"><p>2.5</p></td></tr></tbody></table><p>RRMS: relapsing remitting multiple sclerosis</p><p>EDSS: expanded disability status scale</p><p>Gd+: gadolinium-enhancing</p><p>&nbsp;</p><p>Peginterferon beta‑1a every 2&nbsp;weeks significantly reduced the annualized relapse rate (ARR) by 36% compared to placebo (p=0.0007) at one year (Table 4) with consistent reductions of the ARR noted in subgroups defined by demographic and baseline disease characteristics. peginterferon beta‑1a also significantly reduced the risk of relapse by 39% (p=0.0003), the risk of sustained disability progression confirmed at 12&nbsp;weeks by 38% (p=0.0383) and at 24&nbsp;weeks (post-hoc analysis) by 54% (p=0.0069), the number of new or newly enlarging T2 lesions by 67% (p&lt;0.0001), the number of Gd‑enhancing lesions by 86% (p&lt;0.0001) and the number of new T1 hypointense lesions compared to placebo by 53% (p&lt;0.0001). A treatment effect was observed as early as 6&nbsp;months, with peginterferon beta‑1a 125&nbsp;micrograms every 2&nbsp;weeks demonstrating a 61% reduction (p&lt;0.0001) in new or newly enlarging T2 lesions as compared with placebo. Across relapse and MRI endpoints peginterferon beta‑1a 125&nbsp;micrograms every two weeks showed a numerically greater treatment effect over the peginterferon beta‑1a every four weeks dosing regimen at year 1.</p><p>&nbsp;</p><p>Results over 2&nbsp;years confirmed that efficacy was maintained beyond the placebo controlled first year of the study. Patients exposed to peginterferon beta‑1a every 2&nbsp;weeks showed statistically significant reductions compared to patients exposed to peginterferon beta‑1a every 4&nbsp;weeks over 2&nbsp;years in a post-hoc analysis for endpoints including ARR (24%, p=0.0209), the risk of relapse (24%, p=0.0212), the risk of disability progression with 24&nbsp;week confirmation (36%, p=0.0459), and MRI endpoints (new/enlarging T2 60%, Gd+ 71%, and new T1 hypointense lesions 53%; p&lt;0.0001 for all). In the ATTAIN extension study, long-term efficacy with peginterferon beta‑1a was maintained with continuous treatment up to 4 years as shown by clinical and MRI measures of MS disease activity. Of a total of 1468&nbsp;patients, 658&nbsp;patients continued at least 4&nbsp;years of treatment with peginterferon beta‑1a.</p><p>&nbsp;</p><p>Results for this study are shown in Table 4.</p><p>&nbsp;</p><p>Table 4: Clinical and MRI results</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Peginterferon beta‑1a 125&nbsp;micrograms every 2&nbsp;weeks</p></td><td style="vertical-align:top"><p>Peginterferon beta‑1a 125&nbsp;micrograms every 4&nbsp;weeks</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Clinical endpoints</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>500</p></td><td style="vertical-align:top"><p>512</p></td><td style="vertical-align:top"><p>500</p></td></tr><tr><td style="vertical-align:top"><p>Annualised relapse rate</p></td><td style="vertical-align:top"><p>0.397</p></td><td style="vertical-align:top"><p>0.256</p></td><td style="vertical-align:top"><p>0.288</p></td></tr><tr><td style="vertical-align:top"><p>Rate ratio</p><p>95% CI</p><p>P-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.64</p><p>0.50&nbsp;&ndash;&nbsp;0.83</p><p>p=0.0007</p></td><td style="vertical-align:top"><p>0.72</p><p>0.56&nbsp;&ndash;&nbsp;0.93</p><p>p=0.0114</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of subjects relapsed</p></td><td style="vertical-align:top"><p>0.291</p></td><td style="vertical-align:top"><p>0.187</p></td><td style="vertical-align:top"><p>0.222</p></td></tr><tr><td style="vertical-align:top"><p>HR</p><p>95% CI</p><p>P-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.61</p><p>0.47&nbsp;&ndash;&nbsp;0.80</p><p>p=0.0003</p></td><td style="vertical-align:top"><p>0.74</p><p>0.57&nbsp;&ndash;&nbsp;0.95</p><p>p=0.020</p></td></tr><tr><td style="vertical-align:top"><p>Proportion with 12 week confirmed disability progression*</p></td><td style="vertical-align:top"><p>0.105</p></td><td style="vertical-align:top"><p>0.068</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.068</p></td></tr><tr><td style="vertical-align:top"><p>HR</p><p>95% CI</p><p>P-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.62</p><p>0.40&nbsp;&ndash;&nbsp;0.97</p><p>p=0.0383</p></td><td style="vertical-align:top"><p>0.62</p><p>0.40&nbsp;&ndash;&nbsp;0.97</p><p>p=0.0380</p></td></tr><tr><td style="vertical-align:top"><p>Proportion with 24-week confirmed disability progression*</p></td><td style="vertical-align:top"><p>0.084</p></td><td style="vertical-align:top"><p>0.040</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.058</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>HR</p><p>95% CI</p><p>P-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.46</p><p>(0.26&nbsp;&ndash;&nbsp;0.81)</p><p>p=0.0069</p></td><td style="vertical-align:top"><p>0.67</p><p>(0.41&nbsp;&ndash;&nbsp;1.10)</p><p>p=0.1116</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>MRI endpoints</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>476</p></td><td style="vertical-align:top"><p>457</p></td><td style="vertical-align:top"><p>462</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Mean [Median] no. of new or newly enlarging T2 hyperintense lesions (range)</p></td><td style="vertical-align:top"><p>13.3&nbsp;[6.0]</p><p>(0&nbsp;&ndash;&nbsp;148)</p></td><td style="vertical-align:top"><p>4.1&nbsp;[1.0]</p><p>(0&nbsp;&ndash;&nbsp;69)</p></td><td style="vertical-align:top"><p>9.2&nbsp;[3.0]</p><p>(0&nbsp;&ndash;&nbsp;113)</p></td></tr><tr><td style="vertical-align:top"><p>Lesion mean ratio (95% CI)</p><p>P-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.33&nbsp;(0.27,&nbsp;0.40) p&le;0.0001</p></td><td style="vertical-align:top"><p>0.72&nbsp;(0.60,&nbsp;0.87)</p><p>p=0.0008</p></td></tr><tr><td style="vertical-align:top"><p>Mean [Median] no. of Gd-enhancing lesions (range)</p></td><td style="vertical-align:top"><p>1.4^&nbsp;[0.0]</p><p>(0&nbsp;&ndash;&nbsp;39)</p></td><td style="vertical-align:top"><p>0.2&nbsp;[0.0]</p><p>(0&nbsp;&ndash;&nbsp;13)</p></td><td style="vertical-align:top"><p>0.9&nbsp;[0.0]</p><p>(0&nbsp;&ndash;&nbsp;41)</p></td></tr><tr><td style="vertical-align:top"><p>% reduction vs placebo</p><p>P-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>86</p><p>p&lt;0.0001</p></td><td style="vertical-align:top"><p>36</p><p>p=0.0738</p></td></tr><tr><td style="vertical-align:top"><p>Mean [Median] no. of new T1 hypointense lesions (range)</p></td><td style="vertical-align:top"><p>3.8&nbsp;[1.0]</p><p>(0&nbsp;&ndash;&nbsp;56)</p></td><td style="vertical-align:top"><p>1.8&nbsp;[0.0]</p><p>(0&nbsp;&ndash;&nbsp;39)</p></td><td style="vertical-align:top"><p>3.1&nbsp;[1.0]</p><p>(0&nbsp;&ndash;&nbsp;61)</p></td></tr><tr><td style="vertical-align:top"><p>% reduction vs placebo</p><p>P-value</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>53</p><p>p&lt;0.0001</p></td><td style="vertical-align:top"><p>18</p><p>0.0815</p></td></tr></tbody></table><p>HR: Hazard ratio</p><p>CI: Confidence interval</p><p>* Sustained disability progression was defined as at least a 1&nbsp;point increase from baseline EDSS &ge; 1&nbsp;or 1.5&nbsp;point increase for patients with baseline EDSS of 0, sustained for 12 / 24&nbsp;weeks.</p><p>^n=477</p><p>&nbsp;</p><p>Patients who failed previous MS treatment were not included in the study.</p><p>&nbsp;</p><p>Subgroups of patients with higher disease activity were defined by relapse and MRI criteria as reported below, with the following efficacy results:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients with &ge;1&nbsp;relapse in the previous year and &ge;9&nbsp;T2 lesions or &ge;1&nbsp;Gd+ lesion (n=1401), the annual relapse rate at 1&nbsp;year was 0.39 for placebo, 0.29 for peginterferon beta‑1a every 4&nbsp;weeks and 0.25 for peginterferon beta‑1a every 2&nbsp;weeks.</p><p>Results in this subgroup were consistent with those in the overall population.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients with &ge;2&nbsp;relapses in the previous year and at least 1&nbsp;Gd+ lesion (n=273), the annual relapse rate at 1&nbsp;year was 0.47 for placebo, 0.35 for peginterferon beta‑1a every 4&nbsp;weeks, and 0.33 for peginterferon beta‑1a every 2&nbsp;weeks.&nbsp;</p><p>Results in this subgroup were numerically consistent with those in the overall population but not statistically significant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>The serum half-life of peginterferon beta‑1a is prolonged compared with non‑pegylated interferon beta‑1a. Serum concentration of peginterferon beta‑1a was dose-proportional in the range of 63&nbsp;to 188&nbsp;micrograms as observed in a single dose and a multiple dose study in healthy subjects. Pharmacokinetics observed in multiple sclerosis patients were consistent with those seen in healthy subjects.</p><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>&nbsp;</p><p>Following subcutaneous administration of peginterferon beta‑1a in multiple sclerosis patients, the peak concentration was reached between 1&nbsp;to 1.5&nbsp;days post‑dose.&nbsp; The observed C<sub>max</sub> (mean&plusmn;SE) was 280&nbsp;&plusmn;&nbsp;79&nbsp;pg/mL following repeat dosing of 125&nbsp;micrograms every two weeks.</p><p>&nbsp;</p><p>Subcutaneous peginterferon beta‑1a resulted in approximately 4‑, 9‑, and 13‑fold higher exposure (AUC<sub>168h</sub>) values and approximately 2‑, 3.5‑ and 5‑fold higher C<sub>max</sub>, following single doses of 63<strong>&nbsp;</strong>(6&nbsp;MIU), 125&nbsp;(12&nbsp;MIU), and 188&nbsp;(18 MIU)&nbsp;micrograms respectively, compared to intramuscular administration of 30&nbsp;(6&nbsp;MIU)&nbsp;micrograms non‑pegylated beta‑1a.&nbsp;</p><p>&nbsp;</p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>Following repeat dosing of 125&nbsp;micrograms doses every two weeks by subcutaneous administration, the volume of distribution uncorrected for bioavailability (mean&plusmn;SE) was 481&nbsp;&plusmn;&nbsp;105&nbsp;L.</p><p>&nbsp;</p><p><u>Biotransformation and elimination</u></p><p><u>&nbsp;</u></p><p>Urinary (renal) clearance is postulated to be a major excretory pathway for peginterferon beta‑1a. The process of covalently conjugating a PEG moiety to a protein can alter the <em>in vivo</em> properties of the unmodified protein, including decreased renal clearance and decreased proteolysis thus extending the circulating half‑life. Accordingly, the half-life (t<sub>1/2</sub>) of peginterferon beta‑1a is approximately 2‑fold longer than non‑pegylated interferon beta-1a in healthy volunteers.&nbsp; In multiple sclerosis patients, the t<sub>1/2</sub> (mean&plusmn;SE) of peginterferon beta-1a was 78&nbsp;&plusmn;&nbsp;15&nbsp;hours at steady state. The mean steady state clearance of peginterferon beta‑1a was 4.1&nbsp;&plusmn;&nbsp;0.4&nbsp;L/hr.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>Elderly patients</em></p><p><u>&nbsp;</u></p><p>Clinical experience in patients aged above 65&nbsp;years is limited. However, results from a population pharmacokinetic analysis (in patients up to 65&nbsp;years) suggest that age does not impact peginterferon beta‑1a clearance.&nbsp;</p><p><u>&nbsp;</u></p><p><em>Renal impairment</em></p><p><u>&nbsp;</u></p><p>A single‑dose study in healthy subjects and subjects with various degrees of renal impairment (mild, moderate, and severe renal impairment as well as subjects with end state renal disease) showed a fractional increase in AUC (13‑62%) and C<sub>max</sub> (42‑71%) in subjects with mild (estimated glomerular filtration rate 50&nbsp;to &le;80&nbsp;mL/min/1.73m<sup>2</sup>), moderate (estimated glomerular filtration rate 30&nbsp;to &lt;50&nbsp;mL/min/1.73m<sup>2</sup>), and severe (estimated glomerular filtration rate &lt;30&nbsp;mL/min/1.73m<sup>2</sup>) renal impairment, compared to subjects with normal renal function (estimated glomerular filtration rate &gt;80&nbsp;mL/min/1.73m<sup>2</sup>).&nbsp; Subjects with end stage renal disease requiring 2‑3&nbsp;times haemodialysis weekly showed similar AUC and C<sub>max</sub> as compared to subjects with normal renal function. Each haemodialysis reduced peginterferon beta‑1a concentration by approximately 24%, suggesting that haemodialysis partially removes peginterferon beta‑1a from systemic circulation.</p><p>&nbsp;</p><p><em>Hepatic function </em></p><p><u>&nbsp;</u></p><p>The pharmacokinetics of peginterferon beta‑1a has not been evaluated in patients with hepatic insufficiency.&nbsp;</p><p><s><u>&nbsp;</u></s></p><p>&nbsp;</p><p><em>Gender</em></p><p><u>&nbsp;</u></p><p>No gender effect on the pharmacokinetics of peginterferon beta‑1a was found in a population pharmacokinetic analysis.</p><p>&nbsp;</p><p><em>Race</em></p><p><u>&nbsp;</u></p><p>Race had no effect on the pharmacokinetics of peginterferon beta‑1a in a population pharmacokinetic analysis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Toxicity</u></p><p>&nbsp;</p><p>Following repeated subcutaneous administration of peginterferon beta‑1a in rhesus monkeys at doses up to 400‑fold (based on exposure, AUC) the recommended therapeutic dose; no effects other than the known mild pharmacological responses by rhesus monkeys to interferon beta‑1a were observed after the first and second weekly dose.&nbsp; Repeated dose toxicology studies were limited to 5&nbsp;weeks as exposure was greatly diminished from 3&nbsp;weeks onwards, due to the formation of anti-drug antibodies by rhesus monkeys to human interferon beta‑1a. Therefore, the long-term safety of chronic administration of peginterferon beta‑1a<strong> </strong>to patients cannot be assessed on the basis of these studies.</p><p>&nbsp;</p><p><u>Mutagenesis</u></p><p>&nbsp;</p><p>Peginterferon beta‑1a was not mutagenic when tested in an <em>in vitro</em> bacterial reverse mutation (Ames) test and was not clastogenic in an <em>in vitro</em> assay in human lymphocytes.</p><p>&nbsp;</p><p><u>Carcinogenesis</u></p><p>&nbsp;</p><p>Peginterferon beta‑1a has not been tested for carcinogenicity in animals. Based on the known pharmacology of interferon beta‑1a and clinical experience with interferon beta, the potential for carcinogenicity is expected to be low.</p><p>&nbsp;</p><p><u>Reproductive toxicity</u></p><p>&nbsp;</p><p>Peginterferon beta‑1a has not been tested for reproductive toxicity in pregnant animals. Fertility and developmental studies in rhesus monkeys have been carried out with non-pegylated interferon beta‑1a. At very high doses, anovulatory and abortifacient effects were observed in animals. No information is available on the potential effects of peginterferon beta-1a on male fertility. Upon repeated dosing with peginterferon beta-1a of sexually mature female monkeys, effects on menstrual cycle length and progesterone levels were observed. Reversibility of the effects on menstrual cycle length was demonstrated. The validity of extrapolating these non‑clinical data to humans is unknown.</p><p>&nbsp;</p><p>Data from studies with other interferon beta compounds did not show teratogenic potential. The available information on the effects of interferon beta-1a in the peri- and postnatal periods is limited.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Sodium acetate trihydrate</p><p>Acetic acid, glacial</p><p>Arginine hydrochloride</p><p>Polysorbate 20</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 3 years.

Plegridy can be stored at room temperature (up to 30°C) for up to 7 days as long as it is stored away from light. If Plegridy is at room temperature for a total of 7 days, it should be used or discarded. If it is not clear if Plegridy has been stored at room temperature 7 days or more, it should be discarded.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Store in a refrigerator (2&deg;C to 8&deg;C).</p><p>Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>See section 6.3 for additional information on storage at room temperature.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>A pre‑filled syringe of Plegridy is contained within a single‑use, disposable, spring-powered pen injector called Plegridy Pen. The syringe inside the pen is a 1&nbsp;mL pre‑filled syringe made of glass (Type I) with a bromobutyl rubber stopper and thermoplastic and polypropylene rigid needle shield, containing 0.5&nbsp;mL of solution. &nbsp;A 29&nbsp;gauge, 0.5&nbsp;inch staked needle is pre‑affixed to the syringe.</p><p>&nbsp;</p><p><u>Pack sizes</u></p><p>The Plegridy Pen Initiation Pack contains 1x&nbsp;63&nbsp;micrograms pre‑filled pen (orange labelled pen, 1<sup>st</sup> dose) and 1x&nbsp;94&nbsp;micrograms pre‑filled pen (blue labelled pen, 2<sup>nd</sup> dose) in a protective plastic tray.</p><p>&nbsp;</p><p>Box of two 125&nbsp;microgram pre‑filled pens (grey labelled pens) in a protective plastic tray.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Plegridy pens are for single-use only.</p><p>&nbsp;</p><p>Before use check the pen to be used. It should not have any cracks or damage and the solution should be clear, colourless and not have any particles in it.&nbsp;</p><p>&nbsp;</p><p>Once removed from the refrigerator, the Plegridy pen to be used should be allowed to warm to room temperature (15&deg;C to 30&deg;C) for about 30 minutes.&nbsp;</p><p>&nbsp;</p><p>Do not use external heat sources such as hot water to warm the Plegridy pen</p><p>Titration of Plegridy doses for patients initiating treatment is described in section 4.2.&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Biogen Netherlands B.V.
Prins Mauritslaan 13
1171 LP Badhoevedorp
The Netherlands
Telephone: +31 (0) 20 5422 000
E-mail: medinfo.netherlands@biogen.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 June 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>